Moreover, a significant association between reduced blood CCR6+ ILC2 counts and increased disease activity was observed in CF patients but in none of the other analyzed fibro-inflammatory diseases affecting the gut or joints, further strengthening an organ- and CF-specific role of CCR6+ ILC2s. Here, CCR6 is linked to cystic fibrosis.